GHRP-6

One of the earliest synthetic growth hormone secretagogues, potently stimulating GH release and appetite through the ghrelin receptor but with less selectivity than newer alternatives.

Also known as: Growth Hormone Releasing Peptide-6, SKF-110679, His-DTrp-Ala-Trp-DPhe-Lys-NH2

Regulatory Status

Currently Restricted

Classification date: 2024-06-01

Compounding: Not currently available for compounding

Evidence Summary

Moderate20 human studies published

Key Studies

How It Works

GHRP-6 is a hexapeptide that was among the first synthetic ghrelin mimetics discovered. It activates the GHSR receptor on pituitary somatotrophs, triggering GH release, and also stimulates appetite by mimicking ghrelin's orexigenic effects on the hypothalamus. Compared to ipamorelin, it produces more pronounced elevations in cortisol and prolactin and causes significantly more hunger. It also has some cytoprotective effects on the GI mucosa and heart tissue, though these are secondary to its GH-releasing activity.

Common Applications

Growth hormone stimulationAppetite stimulation in cachexia and wastingBody composition researchGH axis diagnostic testing

Safety & Considerations

Pronounced appetite increase (often intense and disruptive). Water retention, cortisol elevation, and prolactin increase are more common than with ipamorelin. Can cause dizziness, light-headedness, and injection-site reactions. Generally considered inferior to newer, more selective GH secretagogues. Currently not legal for compounding in the US.

Regulatory classifications can change rapidly. The information shown here was last verified on 2024-06-01. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.